Magdalene K Walters, Eline L Korenromp, Anna Yakusik, Ian Wanyeki, André Kaboré, Arthur Poimouribou, Célestine Ki, Coumbo Dao, Paul Bambara, Salam Derme, Théophile Ouedraogo, Kai Hon Tang, Marie-Claude Boily, Mary Mahy, Jeffrey W Imai-Eaton
{"title":"使用 Spectrum AIDS Impact 模块对孕妇艾滋病毒感染率和预防母婴传播覆盖率的数据和估算进行三角测量的指南。","authors":"Magdalene K Walters, Eline L Korenromp, Anna Yakusik, Ian Wanyeki, André Kaboré, Arthur Poimouribou, Célestine Ki, Coumbo Dao, Paul Bambara, Salam Derme, Théophile Ouedraogo, Kai Hon Tang, Marie-Claude Boily, Mary Mahy, Jeffrey W Imai-Eaton","doi":"10.1097/QAI.0000000000003514","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most countries use the Spectrum AIDS Impact Module (Spectrum-AIM), antenatal care routine HIV testing, and antiretroviral treatment data to estimate HIV prevalence among pregnant women. Non-representative programme data may lead to inaccurate estimates HIV prevalence and treatment coverage for pregnant women.</p><p><strong>Setting: </strong>154 countries and subnational locations across 126 countries.</p><p><strong>Methods: </strong>Using 2023 UNAIDS HIV estimates, we calculated three ratios: (1) HIV prevalence among pregnant women to all women 15-49y (prevalence), (2) ART coverage before pregnancy to women 15-49y ART coverage (ART pre-pregnancy), and (3) ART coverage at delivery to women 15-49y ART coverage (PMTCT coverage). We developed an algorithm to identify and adjust inconsistent results within regional ranges in Spectrum-AIM, illustrated using Burkina Faso's estimates.</p><p><strong>Results: </strong>In 2022, the mean regional ratio of prevalence among pregnant women to all women ranged from 0.68 to 0.95. ART coverage pre-pregnancy ranged by region from 0.40 to 1.22 times ART coverage among all women. Mean regional PMTCT coverage ratios ranged from 0.85 to 1.51. The prevalence ratio in Burkina Faso was 1.59, above the typical range 0.62-1.04 in western and central Africa. Antenatal clinics reported more PMTCT recipients than estimated HIV-positive pregnant women from 2015 to 2019. We adjusted inputted PMTCT programme data to enable consistency of HIV prevalence among pregnant women from programmatic routine HIV testing at antenatal clinics with values typical for Western and central Africa.</p><p><strong>Conclusion: </strong>These ratios offer Spectrum-AIM users a tool to gauge the consistency of their HIV prevalence and treatment coverage estimates among pregnant women with other countries in the region.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540279/pdf/","citationCount":"0","resultStr":"{\"title\":\"Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.\",\"authors\":\"Magdalene K Walters, Eline L Korenromp, Anna Yakusik, Ian Wanyeki, André Kaboré, Arthur Poimouribou, Célestine Ki, Coumbo Dao, Paul Bambara, Salam Derme, Théophile Ouedraogo, Kai Hon Tang, Marie-Claude Boily, Mary Mahy, Jeffrey W Imai-Eaton\",\"doi\":\"10.1097/QAI.0000000000003514\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Most countries use the Spectrum AIDS Impact Module (Spectrum-AIM), antenatal care routine HIV testing, and antiretroviral treatment data to estimate HIV prevalence among pregnant women. Non-representative programme data may lead to inaccurate estimates HIV prevalence and treatment coverage for pregnant women.</p><p><strong>Setting: </strong>154 countries and subnational locations across 126 countries.</p><p><strong>Methods: </strong>Using 2023 UNAIDS HIV estimates, we calculated three ratios: (1) HIV prevalence among pregnant women to all women 15-49y (prevalence), (2) ART coverage before pregnancy to women 15-49y ART coverage (ART pre-pregnancy), and (3) ART coverage at delivery to women 15-49y ART coverage (PMTCT coverage). We developed an algorithm to identify and adjust inconsistent results within regional ranges in Spectrum-AIM, illustrated using Burkina Faso's estimates.</p><p><strong>Results: </strong>In 2022, the mean regional ratio of prevalence among pregnant women to all women ranged from 0.68 to 0.95. ART coverage pre-pregnancy ranged by region from 0.40 to 1.22 times ART coverage among all women. Mean regional PMTCT coverage ratios ranged from 0.85 to 1.51. The prevalence ratio in Burkina Faso was 1.59, above the typical range 0.62-1.04 in western and central Africa. Antenatal clinics reported more PMTCT recipients than estimated HIV-positive pregnant women from 2015 to 2019. We adjusted inputted PMTCT programme data to enable consistency of HIV prevalence among pregnant women from programmatic routine HIV testing at antenatal clinics with values typical for Western and central Africa.</p><p><strong>Conclusion: </strong>These ratios offer Spectrum-AIM users a tool to gauge the consistency of their HIV prevalence and treatment coverage estimates among pregnant women with other countries in the region.</p>\",\"PeriodicalId\":14588,\"journal\":{\"name\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540279/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAI.0000000000003514\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003514","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：大多数国家使用 Spectrum AIDS Impact Module (Spectrum-AIM)、产前护理常规 HIV 检测和抗逆转录病毒治疗数据来估计孕妇中的 HIV 感染率。非代表性方案数据可能导致对孕妇艾滋病感染率和治疗覆盖率的估计不准确：方法：使用 2023 年联合国艾滋病规划署的 HIV 估计值，我们计算了三个比率：(1) 孕妇 HIV 感染率与所有 15-49 岁女性的比率（感染率）；(2) 孕前抗逆转录病毒疗法覆盖率与 15-49 岁女性抗逆转录病毒疗法覆盖率的比率（孕前抗逆转录病毒疗法）；(3) 分娩时抗逆转录病毒疗法覆盖率与 15-49 岁女性抗逆转录病毒疗法覆盖率的比率（防止母婴传播覆盖率）。我们开发了一种算法来识别和调整 Spectrum-AIM 中地区范围内不一致的结果，并使用布基纳法索的估计值进行了说明：2022 年，各地区孕妇感染率与所有妇女感染率的平均比率从 0.68 到 0.95 不等。各地区孕前抗逆转录病毒疗法覆盖率为所有妇女抗逆转录病毒疗法覆盖率的 0.40 至 1.22 倍。各地区预防母婴传播的平均覆盖率从 0.85 到 1.51 不等。布基纳法索的流行率为 1.59，高于非洲西部和中部 0.62-1.04 的典型范围。从 2015 年到 2019 年，产前诊所报告的预防母婴传播接受者多于估计的 HIV 阳性孕妇。我们调整了输入的预防母婴传播计划数据，使产前诊所计划性常规 HIV 检测得出的孕妇 HIV 感染率与非洲西部和中部的典型值保持一致：这些比率为 Spectrum-AIM 用户提供了一种工具，用于衡量其孕妇艾滋病毒感染率和治疗覆盖率估计值与该地区其他国家的一致性。
Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.
Background: Most countries use the Spectrum AIDS Impact Module (Spectrum-AIM), antenatal care routine HIV testing, and antiretroviral treatment data to estimate HIV prevalence among pregnant women. Non-representative programme data may lead to inaccurate estimates HIV prevalence and treatment coverage for pregnant women.
Setting: 154 countries and subnational locations across 126 countries.
Methods: Using 2023 UNAIDS HIV estimates, we calculated three ratios: (1) HIV prevalence among pregnant women to all women 15-49y (prevalence), (2) ART coverage before pregnancy to women 15-49y ART coverage (ART pre-pregnancy), and (3) ART coverage at delivery to women 15-49y ART coverage (PMTCT coverage). We developed an algorithm to identify and adjust inconsistent results within regional ranges in Spectrum-AIM, illustrated using Burkina Faso's estimates.
Results: In 2022, the mean regional ratio of prevalence among pregnant women to all women ranged from 0.68 to 0.95. ART coverage pre-pregnancy ranged by region from 0.40 to 1.22 times ART coverage among all women. Mean regional PMTCT coverage ratios ranged from 0.85 to 1.51. The prevalence ratio in Burkina Faso was 1.59, above the typical range 0.62-1.04 in western and central Africa. Antenatal clinics reported more PMTCT recipients than estimated HIV-positive pregnant women from 2015 to 2019. We adjusted inputted PMTCT programme data to enable consistency of HIV prevalence among pregnant women from programmatic routine HIV testing at antenatal clinics with values typical for Western and central Africa.
Conclusion: These ratios offer Spectrum-AIM users a tool to gauge the consistency of their HIV prevalence and treatment coverage estimates among pregnant women with other countries in the region.
期刊介绍：
JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide.
JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
